TLX 주식 개요 상업화 단계의 바이오 제약 회사인 텔릭스 파마슈티컬스는 호주, 벨기에, 일본, 스위스, 미국에서 암 및 희귀 질환을 위한 치료 및 진단용 방사성 의약품의 개발과 상용화에 주력하고 있습니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Telix Pharmaceuticals Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Telix Pharmaceuticals 과거 주가 현재 주가 AU$24.86 52주 최고치 AU$25.80 52주 최저치 AU$9.13 베타 2.41 1개월 변경 11.98% 3개월 변경 사항 23.80% 1년 변경 사항 162.51% 3년 변화 217.09% 5년 변화 1,488.50% IPO 이후 변화 3,958.78%
최근 뉴스 및 업데이트
Telix Pharmaceuticals Limited Completes the Installation of Two New Cyclotron at Telix Manufacturing Solutions in Brussels South, Belgium Dec 19
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent Oct 24 Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy Oct 08 Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy 더 많은 업데이트 보기
Telix Pharmaceuticals Limited Completes the Installation of Two New Cyclotron at Telix Manufacturing Solutions in Brussels South, Belgium Dec 19
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent Oct 24 Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy Oct 08 Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy
Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma Oct 03
Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million. Sep 23
Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent Aug 28
Second quarter 2024 earnings released: EPS: AU$0.035 (vs AU$0.018 loss in 2Q 2023) Aug 23
Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent Jul 30 Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024 Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million. Jun 15
First quarter 2024 earnings released: EPS: AU$0.056 (vs AU$0.027 loss in 1Q 2023) Jun 06
Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent May 28 Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million. May 18
Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024
Now 20% overvalued after recent price rise Apr 12 Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.
Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million. Apr 11
Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million. Apr 09
Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent Mar 26 Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million. Mar 05
Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million. Feb 27
Full year 2023 earnings released: EPS: AU$0.016 (vs AU$0.34 loss in FY 2022) Feb 23 Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024
Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024 Jan 08
Forecast breakeven date pushed back to 2024 Dec 31
Telix Pharmaceuticals Limited Announces Executive Changes Dec 20
Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer Dec 19
Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent Dec 04
Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS Nov 30
Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million. Nov 15
Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million. Nov 02 Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591 Oct 19
Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies Oct 18
Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023 Oct 11
New minor risk - Shareholder dilution Sep 06
Forecast to breakeven in 2023 Aug 25
Forecast to breakeven in 2023 Aug 24
Forecast breakeven date moved forward to 2023 Aug 23
Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 15
Forecast to breakeven in 2023 Jul 21
Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023 Jul 13
Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI Jun 24
Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million. Jun 22
Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion Jun 19
Insider recently bought AU$343k worth of stock Mar 18
Full year 2022 earnings released: AU$0.34 loss per share (vs AU$0.28 loss in FY 2021) Feb 28
Telix Pharmaceuticals Limited Announces Detailed Positive Results from its Completed Pivotal Phase III ZIRCON Trial Feb 20
Forecast breakeven date pushed back to 2024 Jan 18
Telix Pharmaceuticals Limited to Report Q4, 2022 Results on Jan 18, 2023 Jan 12
Telix Pharmaceuticals Limited Announces ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances Dec 22
Insider recently bought AU$73k worth of stock Dec 16
Telix Pharmaceuticals Limited Announces Leadership Changes Dec 05
Telix Pharmaceuticals Limited Announces Illuccix Kit for the Preparation of Gallium Ga 68 Gozetotide Injection Nov 23
Telix Pharmaceuticals Limited Announces That First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy Nov 22
Insufficient new directors Nov 16
Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire Optimal Tracers from Northern California PET Imaging Center. Nov 15
Telix Pharmaceuticals Limited Announces Positive Topline Results from Overseas Phase III Clinical Trial Has Met Clinical Endpoints Nov 11
Telix Pharmaceuticals Limited Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study Nov 07
Forecast breakeven date moved forward to 2023 Oct 22
Telix Pharmaceuticals Limited Presents Preliminary Data on TLX250-CDx Indication Expansion at EANM Oct 18 Telix Pharmaceuticals Limited to Report Q3, 2022 Results on Oct 20, 2022 Telix Pharmaceuticals Limited Announces Health Canada Approves Illuccix for Prostate Cancer Imaging Oct 14
Telix Pharmaceuticals Limited Announces First Patient in New Zealand Dosed with Illuccix Sep 30 Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
Telix Pharmaceuticals Limited and GenesisCare announce First Patient Enroll in ProstACT TARGET Study Sep 27
Telix Pharmaceuticals Limited Reports the Final Results from the IPAX-1 Ph I/II Study of TLX101 Therapy Iodo-Phenylalanine Sep 21
Telix Pharmaceuticals Limited and Atonco S.A.S. Announce That the Final Patient Dosed in A Phase I Study of TLX250-CDx in Patients with Non-Muscle Invasive Bladder Cancer Aug 24
First half 2022 earnings released: AU$0.23 loss per share (vs AU$0.12 loss in 1H 2021) Aug 19
Telix Pharmaceuticals Limited to Report First Half, 2022 Results on Aug 18, 2022 Aug 05
Telix Pharmaceuticals Limited Reports on APAC Regulatory Progress Prostate and Kidney Cancer Imaging Aug 02
Forecast breakeven date moved forward to 2023 Jul 23
Forecast breakeven date pushed back to 2024 Jul 13 Telix Pharmaceuticals Limited Appoints Kevin Richardson as CEO, Telix Americas
Insider recently bought AU$135k worth of stock Jun 08 Telix Pharmaceuticals Limited Announces Management Change
Telix Pharmaceuticals Limited Provides Reimbursement and Launch Updates May 30
Telix Pharmaceuticals Limited Announces First Patient Has Been Dosed in the 'STARLITE 2' Phase II Study of the Company's Investigational Renal Cancer Therapy, TLX250 (177Lu-DOTA-girentuximab), At Memorial Sloan Kettering Cancer Center (MSK) in New York May 05
Non-Independent Non-Executive Director recently bought AU$1.1m worth of stock Apr 30 주주 수익률 TLX AU Biotechs AU 마켓 7D 1.4% 0.1% -2.7% 1Y 162.5% 3.1% 6.5%
전체 주주 수익률 보기
수익률 대 산업: TLX 지난 1년 동안 3.1 %를 반환한 Australian Biotechs 산업을 초과했습니다.
수익률 대 시장: TLX 지난 1년 동안 6.5 %를 반환한 Australian 시장을 초과했습니다.
가격 변동성 Is TLX's price volatile compared to industry and market? TLX volatility TLX Average Weekly Movement 4.4% Biotechs Industry Average Movement 9.8% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.8% 10% least volatile stocks in AU Market 3.1%
안정적인 주가: TLX 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: TLX 의 주간 변동성 ( 4% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 상업화 단계의 바이오 제약 회사인 텔릭스 제약은 호주, 벨기에, 일본, 스위스, 미국에서 암 및 희귀 질환을 위한 치료 및 진단용 방사성 의약품의 개발과 상용화에 주력하고 있습니다. 이 회사는 전립선암 치료용 일루킥스(Illuccix)와 영상 골수염 치료용 TLX66-CDx를 제공합니다. 제품 후보로는 전립선암 치료를 위한 방사성 항체-약물 접합체 TLX591, 신장(신장) 암 치료 및 진단용 TLX250-CDx, 뇌(신경교종) 암 치료용 TLX101-CDx, 골수 조절 치료용 TLX66-CDx, 연조직 육종 치료 및 진단용 TLX300-CDx, 투명세포 신세포 암종 치료용 TLX250 등이 있습니다.
자세히 보기 Telix Pharmaceuticals Limited 기본 사항 요약 Telix Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요? TLX 기본 통계 시가총액 AU$8.28b 수익(TTM ) AU$49.19m 수익(TTM ) AU$645.68m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) TLX 손익 계산서(TTM ) 수익 AU$645.68m 수익 비용 AU$240.33m 총 이익 AU$405.35m 기타 비용 AU$356.16m 수익 AU$49.19m
주당 순이익(EPS) 0.15 총 마진 62.78% 순이익 마진 7.62% 부채/자본 비율 2.9%
TLX 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/21 20:15 장 마감 주가 2024/12/20 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Telix Pharmaceuticals Limited 14 애널리스트 중 9 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Russell Wright Barclay Pearce Capital Pty Limited John Hester Bell Potter Andrew Paine CLSA
11 더 많은 분석가 보기 
